The Risk Benefit Ratio of Glucocorticoids in SLE: Have Things Changed over the Past 40 years?
- 27 July 2017
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 3 (3) , 164-172
Abstract
Opinion statement Purpose of review Glucocorticoids have been the mainstay of treatment in systemic lupus erythematosus for more than half a century. Despite advancements in knowledge concerning the pathophysiology of systemic lupus, the genomic/non-genomic actions of glucocorticoids, and the use of novel therapeutic agents in SLE, the burden of toxicity from glucocorticoid use remains unchanged. Recent findings SLE patients receiving long-term prednisone therapy are at significant risk of morbidity due to permanent organ damage, and prednisone daily dosages above 6 mg have been shown to increase the risk of future organ damage by 50%. Glucocorticoid use carries a higher risk of opportunistic infections, iatrogenic osteoporosis, and avascular necrosis, an increase in risk of cardiovascular events, cataracts, and glaucoma, as well as psychiatric adverse effects like psychosis and manic episodes. There are limited data regarding the relative efficacy of the different glucocorticoid formulations or dosing regimens. Summary The use and dosing of glucocorticoids in SLE remains more art than science, although our knowledge regarding their complex genomic and non-genomic effects, as well as the resultant adverse effects, has greatly expanded over the past half a century.Keywords
Funding Information
- National Institutes of Health (AR 43727 and AR 69572)
This publication has 47 references indexed in Scilit:
- Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroidsAnnals of the Rheumatic Diseases, 2013
- TLR recognition of self nucleic acids hampers glucocorticoid activity in lupusNature, 2010
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Prednisone, Lupus Activity, and Permanent Organ DamageThe Journal of Rheumatology, 2009
- Prevalence and Factors Associated With Metabolic Syndrome in Patients With Rheumatoid Arthritis and Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2008
- Cushing's syndrome without excess cortisolBMJ, 2006
- Corticosteroids and peptic ulcer: meta‐analysis of adverse events during steroid therapyJournal of Internal Medicine, 1994
- The Basophil Adenomas of the Pituitary Body and Their Clinical Manifestations (Pituitary Basophilism)1Obesity Research, 1994
- Up-regulated MHC-class II expression and γ-IFN and soluble IL-2R in lupus nephritisKidney International, 1992
- EFFECT OF DESOXYCORTICOSTERONE AND ASCORBIC ACID ON RHEUMATOID ARTHRITIS°The American Journal of the Medical Sciences, 1950